1h Free Analyst Time
The migraine drugs market is forecasted to grow by USD 1,139.92 million during 2022-2027, accelerating at a CAGR of 6.05% during the forecast period. The report on the migraine drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increase in the number of patients suffering from migraine, the advent of regenerative medicines, and the introduction of new classes of migraine drugs with higher clinical efficacy.
The migraine drugs market is segmented as below:
By End-user
- Hospitals
- Retail
- Online
By Type
- Preventive
- Abortive
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the migraine drugs market covers the following areas:
- Migraine drugs market sizing
- Migraine drugs market forecast
- Migraine drugs market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The analyst recognizes the following companies as the key players in the global migraine drugs market: Abbott Laboratories, AbbVie Inc., Amgen Inc., Amneal Pharmaceuticals Inc., AstraZeneca, Bausch Health Co. Inc., Bayer AG, Dr Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson Services Inc., Merck KGaA, Neurelis Inc., Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., and Winston Pharmaceuticals Ltd.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is rising advances in migraine drugs.'
According to the report, one of the major drivers for this market is the increase in the number of patients suffering from migraine.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- AbbVie Inc.
- Amgen Inc.
- Amneal Pharmaceuticals Inc.
- AstraZeneca Plc
- Bayer AG
- Dr Reddys Laboratories Ltd.
- Eli Lilly and Co.
- Endo International Plc
- GlaxoSmithKline Plc
- H Lundbeck AS
- Johnson and Johnson
- Merck and Co. Inc.
- Neurelis Inc.
- Novartis AG
- Otsuka Holdings Co. Ltd.
- Pfizer Inc.
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
- Winston Pharmaceuticals Ltd.
